Alnylam Pharmaceuticals, Inc. (ALNY)
404.24
-10.96
(-2.64%)
USD |
NASDAQ |
Dec 10, 16:00
406.00
+1.76
(+0.43%)
After-Hours: 20:00
Alnylam Pharmaceuticals Research and Development Expense (Quarterly): 358.81M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc. | 2.492B |
| Glaukos Corp. | 38.07M |
| Bristol Myers Squibb Co. | 2.433B |
| BridgeBio Pharma, Inc. | 112.87M |
| Vertex Pharmaceuticals, Inc. | 977.70M |